CME

CME Group
D

CME

Arincen77/100B

If you had invested in CME Group ago, it would be worth $3,951 today, against $3,836 in SPY and $5,891 in QQQ.

ArincenArincen ScoreBeta

77/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

CME Group key facts

Style
Value stock · 5.7/10Growth 3.9 · Value 5.7 · Dividend 5.4
Day range
306.08 – 309.52
52-week range
218.31 – 329.16
Market capitalization
109.63B USD
P/E
24.98
PEG ratio
2.92
EPS
12.26
Div Yield
1.70%
EPS growth forecast (FY2026)
+10.7%
Volume
0
Beta
0.27
ESG score
62.0/100Environment 61 · Social 61 · Governance 64
Sector
Financial Services
Industry
Financial - Data & Stock Exchanges
CEO
Terrence A. Duffy
Employees
4K
IPO date
6 Dec 2002

CME Group earnings

Next earnings · Q4 FY2026
EPS estimate
3.01 USD
Revenue estimate
1.76B USD
Last quarter · Q3 FY2026
EPS3.02Beat +1.0%Revenue1.74BBeat +1.3%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20283.55———1.94B———
Q2 FY20283.54———1.94B———
Q1 FY20283.69———2.00B———
Q4 FY20263.01——+8.66%1.76B——+6.89%
Q3 FY20262.993.02+1.00%+12.69%1.71B1.74B+1.31%+12.99%
Q2 FY20262.912.99+2.75%+1.01%1.68B1.71B+1.43%+0.84%
Q1 FY20263.343.36+0.60%+20.00%1.87B1.88B+0.28%+14.48%
Q4 FY20252.752.77+0.73%+9.92%1.65B1.65B+0.09%+8.09%
Q3 FY20252.632.68+1.90%0.00%1.53B1.54B+0.49%-2.95%
Q2 FY20252.912.96+1.72%+15.63%1.69B1.69B+0.38%+10.41%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

CME Group analyst forecast

12-month price target
317.91 USD
+3.79%

Analysts' 1-year price targets range from 227.00 to 367.00, with an average of 317.91.

Past year
1-year forecast
Strong sellStrong buy
Buy
15 ratings
Buy
8
Hold
6
Sell
1

12-month price target

Highest target367.00
Average target317.91
Lowest target227.00
Current price306.29

CME Group valuation

Price to earnings ratio (TTM)
24.98
Forward P/E (FY2026)
24.69
Price to sales (TTM)
15.72
Price to book
4.13
EV / EBITDA (TTM)
16.70

Capital structure

Market capitalization
109.63B USD
+
Total debt
3.43B USD
−
Cash and short-term investments
2.33B USD
=
Enterprise value
110.73B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)21.45————
FY2027 (est.)23.1021.45———
FY2026 (est.)24.6923.10———
Now (TTM)24.9823.2715.724.1316.70
FY202524.4322.0215.063.4216.83
FY202423.9720.7913.613.1516.67
FY202323.7420.6913.552.8316.32
FY202222.6918.1812.022.2415.20
FY202131.3028.7917.462.9921.01

CME Group against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Intercontinental Exchange, S&P Global, Moody's, Nasdaq, MSCI, and Coinbase Global, the US Financial - Data & Stock Exchanges companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median25.0
    18.536.7
  • Gross marginAbove its median86.1%
    82.2%86.1%
    Against its peers: 1 of 7Peers' median 69.2%
  • Operating marginHighest in 5 years64.9%
    56.4%64.9%
    Against its peers: 1 of 7Peers' median 40.5%
  • Net marginHighest in 5 years62.0%
    53.6%62.0%
    Against its peers: 1 of 7Peers' median 27.6%
  • Return on equityHighest in 5 years14.1%
    9.6%14.1%
    Against its peers: 4 of 6Peers' median 14.3%
  • Free cash flow marginHighest in 5 years64.3%
    48.5%64.3%
    Against its peers: 1 of 7Peers' median 33.9%
  • Revenue growthBelow its median6.4%
    -4.0%11.1%
    Against its peers: 7 of 7Peers' median 9.1%
  • EPS growthAt its median15.4%
    1.5%24.2%
    Against its peers: 5 of 7Peers' median 19.7%
  • Debt to EBITDALowest in 5 years0.59×
    0.59×0.88×
    Against its peers: 1 of 7Peers' median 3.11×
  • Current ratioHighest in 5 years1.03
    1.011.03
    Against its peers: 3 of 7Peers' median 1.01

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

CME Group growth and profitability

Revenue (TTM)
6.97B USD
Net income (TTM)
4.40B USD
Gross margin
84.32%
Operating margin
65.66%
Net margin
63.12%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY20256.52B+6.37%4.04B+14.71%86.09%64.86%62.02%5.78B+14.63%
FY20246.13B+9.88%3.53B+9.29%86.13%64.13%57.52%5.04B+8.01%
FY20235.58B+11.15%3.23B+19.89%85.15%61.58%57.83%4.67B+16.19%
FY20225.02B+7.03%2.69B+2.07%85.00%60.08%53.61%4.02B+2.28%
FY20214.69B-3.97%2.64B+25.23%82.15%56.40%56.22%3.93B+17.10%

CME Group revenue breakdown

By product

FY2025
clearing and transaction fees: 81.0%MarketData: 12.3%OtherRevenue: 6.7%81.0%clearing and transaction fees12.3%MarketData6.7%OtherRevenue
SegmentRevenueShare of revenueChange on the year
clearing and transaction fees5.28B81.0%+5.9%
MarketData803.10M12.3%+13.1%
OtherRevenue436.40M6.7%+1.1%

How CME Group makes its money

clearing and transaction fees5.28B 81.0%
MarketData803.10M 12.3%
OtherRevenue436.40M 6.7%
Revenue6.52B 100.0%
Cost of revenue907.00M 13.9%
Gross profit5.61B 86.1%
Selling and administration150.50M 2.3%
Other operating expenses1.23B 18.9%
Operating income4.23B 64.9%
Tax1.27B 19.5%
Net income4.04B 62.0%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

CME Group dividends

Annual dividend
5.20 USD
Dividend yield (indicated)
1.70%
Payout ratio
52.61%
Years of dividend growth
16
Frequency
Quarterly
Next payment
1.30 USD
Next ex-dividend date
11 Dec 2026
Next payment date
30 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share5.004.604.404.003.603.403.002.802.642.40

CME Group financial health

Cash and short-term investments
2.33B USD
Total debt
3.43B USD
Net cash
-1.10B USD
Free cash flow (TTM)
4.33B USD
Current ratio
1.02
Debt to equity
0.13
Piotroski score
6 / 9
Altman Z-score
0.62

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20254.54B3.42B4.19B
FY20243.01B3.43B3.60B
FY20233.02B3.43B3.38B
FY20222.82B3.44B2.97B
FY20212.95B3.45B2.28B

CME Group ownership

Institutions
73.16%
Institutional holders
1,528 (-247)
Free float
98.62%

Who owns the shares

Institutions 73.2% Others 26.8%
As of 30 Sept 2026

Shares free to trade

Free float 353.01M shares ·98.6% Closely held 4.93M shares ·1.4%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 2026050.0018.01K
Q3 20261349.46K28.47K
Q2 20262339.01K65.70K
Q1 202627125.68K73.83K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025359.63M360.23M+0.08%
FY2024359.39M359.94M+0.12%
FY2023359.02M359.50M+0.09%
FY2022358.71M359.18M+0.07%
FY2021358.34M358.93M+0.11%

Source: Financial Modeling Prep

Signals
هشام منسي
هشام منسي
2 years ago
buy
CME
CMECME Group @228.17
2024-11-14 07:38
CME@228.17 Chart
Profit
957.50
USD
8.39%
More
Related Instruments

Title: CME Group

Sector: Financial Services
Industry: Financial - Data & Stock Exchanges
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.

Common questions about CME Group stock